Neuro Path Finder — AI Screening Support for Parkinson's

The problem: early Parkinson's hides in plain sight

Parkinson's disease and the wider family of Parkinsonian syndromes rarely announce themselves. The earliest signals — a subtle rest tremor, slower movement, a softer voice, changes in handwriting, disturbed sleep, reduced sense of smell — are easy to attribute to ageing, stress or unrelated conditions. In a busy consultation of ten to fifteen minutes, a clinician simply cannot work through every relevant prompt for every patient. The result is well documented in neurology: meaningful diagnostic delay, and motor symptoms that often only surface once a substantial share of dopaminergic neurons has already been lost.

A rigid paper or digital questionnaire is not the answer either. Ask everyone the same long list and you waste the patient's time on irrelevant items, fatigue the respondent, and still miss the follow-up that actually mattered. What clinicians need is a tool that adapts — one that listens to each answer and asks the next relevant question, then hands back something structured and trustworthy that supports the preliminary evaluation without ever implying a diagnosis. That is the gap Neuro Path Finder is designed to close.

An honest note up front: this is a capability deep-dive, not a delivered client win. The figures further down are peer-reviewed sector benchmarks for the underlying technology, framed exactly as our case-study honesty policy requires — not validated outcomes for this specific tool. Neuro Path Finder was developed with input from a board-certified neurologist specialising in movement disorders.

How it works: an adaptive, condition-driven questionnaire

The core idea is a dynamic questionnaire that branches in real time. Instead of a fixed form, the system holds a structured map of Parkinsonian indicators and their relationships, and uses each response to decide what to ask next. If early answers point toward a tremor-dominant pattern, the tool drills into that line of enquiry; if they point elsewhere, it follows a different branch and skips what is no longer relevant. The patient only ever sees the questions that earn their place.

In practice the flow runs through four stages, and these are the steps a clinician or product owner would recognise:

• Adaptive intake. A condition-driven questionnaire adapts as each answer arrives, asking only the relevant follow-ups and keeping the session short and focused.
• Privacy-first capture. No personally identifiable information is collected. Age is the only demographic parameter used, because age genuinely shifts clinical context for Parkinsonian conditions.
• Classify. An AI layer maps the completed set of responses to predefined likelihood levels for the relevant conditions — a structured, repeatable interpretation rather than a free-text guess.
• Summarise. The tool consolidates everything into one clinician-friendly summary: the likelihood category, the responses that drove it, and the points worth probing in person.

The output is deliberately conservative. It is an indicative likelihood summary that points a clinician toward the right next questions and, where appropriate, onward referral — not a verdict. The clinician reads it, weighs it against the examination in front of them, and decides. The machine never closes the loop on its own.

The technology and our approach

Under the hood, the screening logic combines two complementary ideas. The branching itself is rule-based and transparent: it encodes how movement-disorder clinicians actually reason, so every path through the questionnaire can be explained and audited. Layered on top, machine-learning classification turns the pattern of answers into a calibrated likelihood. This mirrors the wider machine learning evidence base, where questionnaire- and scale-based models — for example those built on the MDS-UPDRS instrument — have reached very high reported accuracy and AUC on structured inputs.

We treat explainability and calibration as first-class requirements, not afterthoughts. A likelihood score is only useful to a clinician if they can see why it landed where it did, and trust that "high likelihood" means what it claims across the population the tool will actually serve. So the design favours interpretable features, confidence reporting, and a clear audit trail over a black-box label.

Around the model sits the product. Building this responsibly is as much an engineering and governance task as a modelling one: secure data handling, a clean clinician-facing interface, and integration that fits existing workflows rather than fighting them. That is where our AI implementation and application development work comes in — turning a promising model into a dependable, privacy-respecting tool a clinic can actually run. Privacy-by-design is structural here, not cosmetic: collecting no PII and limiting demographics to age keeps the data footprint minimal from the very first question.

Who it's for, and the value it adds

Neuro Path Finder is built for the people and settings where early Parkinsonian signs are most likely to be seen first: neurology clinics, movement-disorder services, and the broader healthcare teams — including primary and geriatric care — who triage patients before specialist review. The value is practical and measured:

• Sharper consultations. Clinicians spend their limited minutes on judgement and examination, not on remembering and reciting a long checklist.
• Consistency. Every patient is screened against the same structured logic, which reduces the variation that creeps in when busy clinicians cover questions from memory.
• Earlier attention. Surfacing a structured likelihood summary helps the right patients reach specialist assessment sooner, where management can begin earlier.
• Privacy as a default. No identifiable data means a smaller risk surface and an easier conversation with patients, data-protection officers and regulators.

Honest results — and the regulatory framing

We will not invent a number. What we can share is the published evidence for this class of technology, presented exactly as a benchmark and not as our own validated metric. Across modalities, peer-reviewed AI Parkinson's-detection studies report a broad span of accuracy, and questionnaire- or scale-based machine-learning models on structured inputs have reported particularly strong figures. Those numbers describe what the approach can achieve in research settings — they are sector benchmarks, not Neuro Path Finder's own validated performance, and any real-world claim would have to come from a prospective study on the tool's own data and population.

The regulatory and clinical framing is equally important. Neuro Path Finder is screening support only. It produces an indicative likelihood summary, not a diagnosis, and it is built to keep a clinician in the loop at every step. In the EU, software that contributes to clinical decision-making for screening of a condition like Parkinson's would fall under the Medical Device Regulation (EU MDR), and we design with that awareness from the start — clear intended-use boundaries, traceability, risk management and human oversight. Clinical deployment requires appropriate regulatory clearance and clinician oversight; the tool is built to support that pathway, not to bypass it. For a closely related example of the same principles in cardiology, see our AI ECG decision-support write-up, or our clinical NLP discharge-summary work for documentation.

How we'd run a pilot

For a clinic that wants to explore this, we keep the first step small, honest and clinician-led. A typical engagement starts with a focused scoping session to pin down the intended use, the patient pathway and the regulatory posture. From there we would validate the adaptive logic and likelihood calibration against the clinic's own anonymised cohort, run the tool alongside existing practice (never instead of it), and report real, measured performance on that data — sensitivity, specificity and clinician feedback — rather than borrowed benchmarks. If the evidence supports it, we then plan the route to a compliant, supervised rollout. You can see indicative engagement structures on our pricing page, and the fastest way to start is a free 30-minute consultation via the contact form. Tell us the pathway you want to support, and we will scope an honest pilot — with the clinician firmly in control of every decision.